Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Open source discovery of starting points for next generation chemoprotective antimalarial drugs (Biofocus 1)

ABSTRACT: Metabolic examination/confirmation of resistance mutations observed in study

ORGANISM(S): Human Homo Sapiens

TISSUE(S): Parasite

SUBMITTER: Edward Owen

PROVIDER: ST001074 | MetabolomicsWorkbench | Thu Feb 15 00:00:00 GMT 2018

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Similar Datasets

Plasmodium Niemann-Pick Type C1-Related Protein is a Druggable Target Required for Parasite Membrane Homeostasis

Project description:Metabolic examination/confirmation of resistance mutations and GFP tagging observed in study

2019-02-15 | ST001149 | MetabolomicsWorkbench

Combining stage - specificity and metabolomic profiling to advance drug discovery for malaria

Project description:Metabolic examination/confirmation of MoA stage-specificity observed in study

2019-07-09 | ST001232 | MetabolomicsWorkbench

Lentiviral-driven discovery of cancer drug resistance mutations

Project description:Identifying resistance mutations in a drug target provides crucial information. Lentiviral transduction creates multiple types of mutations due to the error-prone nature of the HIV-1 reverse transcriptase (RT). We optimized and leveraged this property to identify drug resistance mutations, a technique we term LentiMutate. After validating this technique by identifying clinically relevant EGFR resistance mutations, we applied this technique to two additional anti-cancer drugs, imatinib and AMG 510. We find novel deletions in BCR-ABL1 that confer resistance to BCR-ABL1 inhibitors and point mutations in the AMG 510 binding pocket or oncogenic non-G12C mutations, in KRAS-G12C or wild-type KRAS, respectively, that confer resistance to AMG 510. LentiMutate may prove highly valuable to clinical and preclinical cancer drug development.

2021-07-28 | GSE180965 | GEO

Herbicidal properties of antimalarial drugs.

Project description: Not available

| S-EPMC5374466 | biostudies-literature

Integration of Proteomics, Phosphoproteomics and Kinomics Enables the Discovery of Anticancer Drugs for Pancreatic Cancer

Project description:Here we performed proteomic examination of surgical specimens. This lead to the prediction of a number of drugs that induced apoptosis in the patient-derived cell lines.

2022-06-28 | MSV000089751 | MassIVE

Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in Mycobacterium abscessus

Project description:Regulation of M. abscessus gene expression in WT or dosR mutant and treated with artemisinin

2024-05-12 | GSE174310 | GEO

Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs [lenti]

Project description:Identifying resistance mutations in a drug target provides crucial information. Lentiviral transduction creates multiple types of mutations due to the error-prone nature of the HIV-1 reverse transcriptase (RT) and we show this property can be leveraged to identify mutations that confer resistance to targeted anti-cancer drugs, a technique we term “LentiMutate”. First, we improved LentiMutate by making the lentiviral RT more error-prone. Next, we applied this technique to two anti-cancer drugs, imatinib and AMG 510. We find novel deletions in BCR-ABL that confer resistance to BCR-ABL inhibitors and point mutations in the AMG 510 binding pocket or oncogenic non-G12C mutations, in KRAS-G12C or wild-type KRAS, respectively, that confer resistance to AMG 510. LentiMutate may prove highly valuable to clinical and preclinical cancer drug development

2021-07-25 | GSE164663 | GEO

Lentiviral-based mutagenesis to identify mutations that confer resistance to anti-cancer drugs [umi]

Project description:Identifying resistance mutations in a drug target provides crucial information. Lentiviral transduction creates multiple types of mutations due to the error-prone nature of the HIV-1 reverse transcriptase (RT) and we show this property can be leveraged to identify mutations that confer resistance to targeted anti-cancer drugs, a technique we term “LentiMutate”. First, we improved LentiMutate by making the lentiviral RT more error-prone. Next, we applied this technique to two anti-cancer drugs, imatinib and AMG 510. We find novel deletions in BCR-ABL that confer resistance to BCR-ABL inhibitors and point mutations in the AMG 510 binding pocket or oncogenic non-G12C mutations, in KRAS-G12C or wild-type KRAS, respectively, that confer resistance to AMG 510. LentiMutate may prove highly valuable to clinical and preclinical cancer drug development

2021-07-25 | GSE164661 | GEO

In Silico Mining for Antimalarial Structure-Activity Knowledge and Discovery of Novel Antimalarial Curcuminoids.

Project description: Not available

| S-EPMC6273176 | biostudies-other